Irritable Bowel Syndrome (IBS) Research and CBD (Cannabidiol)
Care and Feeding of Your Endocannabinoid System
Human Already Have an Endocannabinoid System One of the greatest advantages for publicly traded companies is their ability to raise capital in public markets. Capital can be used to fund research and development (R&D), fund capital expenditure, or even be used to pay off existing debt. This advantage is even more crucial for small biotechnology companies. Because of long lead... ContinueClinical Endocannabinoid Deficiency
Clinical Endocannabinoid Deficiency Could Explain Why You’re Sick Dr. Ethan Russo is one of the world’s foremost experts in cannabis research. Not only is he a board-certified neurologist, psychopharmacology researcher, and an accomplished author in many scientific journals, he’s also the former Senior Medical Advisor to GW Pharmaceuticals – a global leader in the development of cannabis-based medicines. Today, he... Continue
Irritable Bowel Syndrome (IBS) Research Continued
- Cannabidiol in inflammatory bowel diseases: A brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
- Therapeutic potential of cannabinoid-based drugs
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
- CBD and the gut: New developments and emerging concepts
- Endocannabinoids and the gastrointestinal tract
- CBD and gastrointestinal motility
